| Name | Title | Contact Details |
|---|
We buy consumer-leading Amazon FBA brands and elevate them to their full potential. Tap into our unparalleled team to successfully grow your business.
TCGplayer is the leading online technology platform for the collectibles industry. We are revolutionizing the collectibles marketplace by connecting thousands of buyers and sellers from around the world. We leverage our ecommerce and data management tools to power sales through physical stores, websites, mobile apps and the TCGplayer Marketplace. What sets TCGplayer apart is our community mindset; it is ingrained in how we operate. We emphasize the entire customer experience, working with buyers and sellers from end-to-end to harness our passion for innovation and create a diverse community of collectible enthusiasts across our platform. And, when it comes to our employees, we work to ensure our team is the strongest it can possibly be, both in and out of the workplace. We know our employees are the lifeblood of our company and at TCGplayer, our talented team is creating an entire industry - and defining its future - every single day. Our success depends on every team member, which is why we also ensure that every TCGplayer employee gets stock options and flexible and progressive benefits. TCGplayer is a nationally recognized and award-winning workplace. Fortune.com declared us one of the 100 Best Workplaces for Women, and we`ve been named one of the Best Companies to Work for in New York two years in a row.
Recently merged with Pinch Media, Flurry is among the largest smartphone application analytics and monetization platforms in the world, now tracking more than 80% of all consumers across iPhone, iPod Touch and Android devices.
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.